What it's actually good for
Citicoline (cytidine-5-diphosphocholine, or CDP-choline) is a compound your body makes while building phosphatidylcholine, a core component of cell membranes, including neuronal ones. Taken as a supplement, it splits into choline and cytidine, which the body converts to uridine. That's a meaningfully different mechanism than Alpha-GPC, a more direct free-choline donor: citicoline supplies both a choline source for acetylcholine synthesis and a pyrimidine (cytidine/uridine) that feeds membrane-phospholipid repair. Not a duplicate of Alpha-GPC — a different route to a related outcome, with its own trial history and its own gaps.
Citicoline has decades of use as a prescription drug for stroke and cognitive impairment in Europe and Asia, so it has a genuinely large clinical literature — but "large" and "consistently positive" aren't the same thing, and the honest read is more mixed than supplement marketing suggests.
What the research says
Memory in older adults with age-related decline (Grade B). The strongest single trial here is Nakazaki et al. (2021): 100 adults aged 50-85 with self-reported age-associated memory impairment took 500 mg/day of citicoline (as Cognizin) for 12 weeks and showed significant improvement over placebo on episodic memory and a composite memory score. That's a real, well-designed RCT in the population most likely to benefit. It's a B, not an A, because it's one trial — the broader meta-analytic literature in dementia/MCI populations found a positive pooled effect but rated the underlying studies as low quality, with only two of seven trials being true RCTs.
Stroke recovery doesn't hold up (worth knowing, not a claim we make). Citicoline has a long history as a stroke treatment, and a 2015 systematic review of 14 RCTs found a positive effect on MMSE scores in acute ischemic stroke at some doses. But the largest, best-designed trial — the 2012 ICTUS trial, 2,298 patients across three countries — found no difference in functional recovery between citicoline and placebo, and was stopped early for futility. When the biggest, most rigorous trial contradicts smaller positive ones, the biggest trial usually wins. We don't list stroke recovery as a claim here for that reason.
Attention and focus in healthy adults (Grade C). The evidence thins further once you move from "older adults with memory complaints" to "generally healthy people wanting sharper focus." A 60-person trial in women aged 40-60 found fewer attention-test errors at 250-500 mg/day over 28 days — real, statistically significant, but a small trial in a narrow age band. This is the honest gap: citicoline is better-studied in people with some cognitive decline than in healthy adults chasing an edge.
How much, and which form
250-500 mg/day is the range used in the positive memory and attention trials, and what most consumer products are built around. Look for Cognizin, the patented, standardized citicoline form used in most cited RCTs — generic "citicoline sodium" from an unspecified source hasn't been tested to the same degree. Higher clinical doses (up to 2,000 mg/day) show up in stroke research but aren't the basis for supplement dosing.
Safety & interactions
Citicoline has a good safety record across trials running 12 weeks to 3 years, with adverse-event rates similar to placebo — mild headache, GI upset, or insomnia are the most common complaints. Because it raises cholinergic and dopaminergic activity, people taking levodopa or other cholinergic/dopaminergic medications should check with a physician first. There's a theoretical interaction with blood thinners given choline's role in platelet biology, so caution is warranted on anticoagulants. It is not a treatment for stroke, dementia, or Alzheimer's disease, and U.S. regulators have sent warning letters to sellers who've implied otherwise. This is informational, not medical advice — check with a clinician before starting.
How we picked the brand
A citicoline product earns a spot when it uses Cognizin (the studied ingredient) rather than an unspecified citicoline source, doses at 250 mg/capsule to match trial dosing, and comes from a manufacturer with third-party testing and NSF-certified production.